The gabapentinoid drugs gabapentin and pregabalin are key front‐line therapies for various
neuropathies of peripheral and central origin. Originally designed as analogs of GABA , the …

Recent studies have revealed extensive neocortical pathology in multiple sclerosis (MS).
The hippocampus is a unique archaeocortical structure understudied in MS. It plays a central …

Diffuse noxious inhibitory controls (DNICs) utilize descending inhibitory controls through
poorly understood brain stem pathways. The human counterpart, conditioned pain modulation, …

Human autoantibodies to contactin-associated protein-like 2 (CASPR2) are often associated
with neuropathic pain, and CASPR2 mutations have been linked to autism spectrum …

The α 2 δ-1 subunit of voltage-gated calcium channels is upregulated after sensory nerve
injury and is also the therapeutic target of gabapentinoid drugs. It is therefore likely to play a …

Neuropathic pain remains poorly treated for large numbers of patients, and little progress
has been made in developing novel classes of analgesics. To redress this issue, ziconotide (…

Background Following neuropathy α2‐adrenoceptor‐mediated diffuse noxious inhibitory
controls (DNIC), whereby a noxious conditioning stimulus inhibits the activity of spinal wide …

Treating neuropathic pain is challenging and novel non–opioid-based medicines are needed.
Using unbiased receptomics, transcriptomic analyses, immunofluorescence, and in situ …

Objective There are limited clinical treatments for temporomandibular joint (TMJ) pathologies,
including degenerative disease, disc perforation and heterotopic ossification (HO). One …

Neuropathic pain represents a substantial clinical challenge; understanding the underlying
neural mechanisms and back-translation of therapeutics could aid targeting of treatments …